GET DAILY SIGNALSAllogene Therapeutics (ALLO) Analyst Targets Signal +630% Upside Potential
Key Takeaways
- The central $9 price target is the arithmetic mean of ten verified analyst price targets for Allogene Therapeutics, Inc. (ALLO), rounded from a calculated mean of roughly $8.99.
- At a recent closing price near $1.23, reaching $9 would require an upside of about 630%, a very large move for a clinical-stage biotechnology company.
- Analyst targets span a wide range from $3.85 (Bernstein) to $14 (Canaccord Genuity), reflecting sharply different views on the pipeline's probability of success.
- The strongest support comes from positive interim data for cema-cel in the pivotal ALPHA3 trial and a cash runway that management says extends into 2029.
- The biggest risks are binary clinical-trial outcomes, continued cash burn, and a stock that remains well below its 52-week high near $4.46.
- For more on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Explore Trending AI Robots to see how AI-driven tools are being applied to stock and ETF analysis.
Analyst Price Targets and Consensus View
The $9 central target represents the arithmetic mean of ten attributable analyst price targets, not an official published consensus. The full range is wide, from $3.85 to $14, and the average works out to roughly $8.99 before rounding. Individual targets include Canaccord Genuity's $14 (Buy, September 2026), Piper Sandler's $10 (Buy), Jefferies' $10 (Buy), RBC Capital's $9 (Buy), Baird's $9 (Outperform), Citizens JMP's $8 (Market Outperform), UBS's $8 (Buy), Oppenheimer's $7 (Buy), H.C. Wainwright's $11 (Buy), and Bernstein's $3.85 (Market Perform).
The dispersion matters more than the average. Bulls emphasize that the ALPHA3 interim futility analysis showed cema-cel achieving a 58.3% minimal residual disease (MRD) clearance rate versus 16.7% for observation, which they see as de-risking an "off-the-shelf" CAR T platform. More cautious analysts, such as Bernstein, keep materially lower targets tied to clinical-execution risk, durability of response, and funding. J.P. Morgan upgraded ALLO from Underweight to Neutral in April 2026, reflecting a slightly more constructive but still guarded stance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Allogene Therapeutics, Inc. (ALLO) is a clinical-stage immuno-oncology company developing allogeneic CAR T therapies for cancer and autoimmune disease. With the stock trading near $1.23 against a 52-week range of roughly $1.04 to $4.46, the gap to $9 represents an upside of about 630%. That is a very large move and would require not only favorable clinical data but also a substantial re-rating of a company that currently generates minimal revenue.
The path runs primarily through cema-cel, the lead candidate in the pivotal Phase 2 ALPHA3 trial for first-line large B-cell lymphoma, plus ALLO-329 in autoimmune disease. Management has indicated a cash runway into 2029, which reduces near-term dilution risk but does not remove the binary nature of the readouts ahead.
What Could Support a Move Toward the Target
The most important catalyst is the ALPHA3 trial itself. The April 2026 interim futility analysis reported a 58.3% MRD clearance rate for cema-cel versus 16.7% for observation, with a favorable safety profile and potential for outpatient use. If final efficacy data confirm this signal, cema-cel could target a first-line lymphoma market management has sized in the billions of dollars. Broadening adoption of MRD testing across oncology, and the U.S. Food and Drug Administration's May 2026 approval of an MRD-guided therapy in bladder cancer, lend credibility to the trial's design. ALLO-329, with proof-of-concept data expected, offers a second, non-oncology growth avenue in autoimmune disease.
What Could Prevent the Target From Being Reached
Clinical-stage biotechs carry binary risk: a failed or mixed readout could compress the stock sharply. Allogeneic CAR T therapies still face questions about durability of response, manufacturing consistency, and competition from autologous CAR T products. The company continues to post significant net losses and burns cash, and while the runway extends into 2029, future dilution or financing remains possible. The wide $3.85-to-$14 target range itself signals that analysts disagree fundamentally about whether the platform will translate into commercial success.
Technical Levels and Market Structure
ALLO trades near the bottom of its 52-week range, with a recent low around $1.04 acting as a key support level and the $1.00 mark serving as a psychological floor. On the upside, the stock would need to reclaim multiple resistance levels, with the 52-week high near $4.46 representing the first major structural hurdle well before any approach toward $9. The long-term trend remains downward, with the shares having declined steadily through late 2026 and trading well below their 20-day average.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though firms rarely state a precise date and timelines differ. Investors should monitor the next quarterly earnings report, updated cash guidance, progress on ALPHA3 enrollment and any interim event-free survival analysis, ALLO-329 proof-of-concept data, and analyst revisions to ratings and targets. Regulatory and MRD-adoption developments in oncology also matter, as do broader biotech sector conditions and interest-rate expectations.
Using Tickeron AI Tools in My Research
In my analysis of names like ALLO, I often turn to Tickeron’s AI Daily Buy/Sell Signals to track technical shifts and generate signals based on market conditions. This tool helps me monitor volatile biotech stocks more efficiently and spot potential changes in trend without manual effort. It has become a regular part of how I evaluate opportunities in the sector.
Final Assessment
The $9 central target is the average of ten analyst price targets spanning $3.85 to $14, implying a very large move of roughly 630% from a recent price near $1.23. Reaching that level would likely require definitive success for cema-cel in ALPHA3, progress in ALLO-329, and a meaningful re-rating of the entire allogeneic CAR T platform. The strongest support comes from encouraging interim MRD data and a cash runway into 2029; the principal obstacles are binary clinical risk, ongoing losses, and a wide analyst divergence of opinion. Investors should weigh these factors and monitor upcoming data readouts and financial updates rather than treating the average target as a forecast or guarantee.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALLO's Stochastic Oscillator remains in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +3.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in 190 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALLO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.974) is normal, around the industry mean (3.037). P/E Ratio (-1.864) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ALLO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the Dead Cat Bounce (Bearish) Pattern?
What Are Silver Futures and How Can Silver Futures Be Used for Hedging Purposes?
What are the most significant risks associated with investing in Starbucks?
Understanding Index Futures: An Overview
What is Cyber Monday and How Did It Become a Global Phenomenon?
General Information
a developer of allogeneic chimeric antigen receptor therapy
Industry Biotechnology
Advertisement